Condensed Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 122,940	$ 208,892
Short-term investments	62,905	50,441
Accounts receivable	27,844	22,934
Prepaid clinical development costs	373	1,138
Inventories, net	29,232	34,394
Other prepaid and current assets	9,184	11,173
Total current assets	252,478	328,972
Restricted cash	50,000	50,000
Property and equipment, net	361	664
Right of use operating lease assets	1,085	1,898
Intangible assets	56	56
Total assets	303,980	381,590
Current liabilities:
Accounts payable	12,832	17,559
Accrued clinical development costs	11,420	7,013
Other accrued liabilities	30,066	30,410
Revenue interest liability	21,972	11,295
Deferred revenue from collaborations	5,028	5,683
Operating lease liabilities	957	1,392
Total current liabilities	82,275	73,352
Convertible notes, net of issuance costs	259,080	258,280
Revenue interest liability	253,977	245,744
Operating lease liabilities	135	524
Deferred revenue from collaborations	211	634
Total liabilities	595,678	578,534
Commitments and contingencies (Note 5)
Stockholders’ equity:
Preferred stock, $0.001 par value; 5,000,000 shares authorized and no shares issued or outstanding as of June 30, 2022 and December 31, 2021	0	0
Common stock, $0.001 par value; 240,000,000 shares authorized as of June 30, 2022 and 120,000,000 shares authorized as of December 31, 2021; 66,590,172 shares issued at June 30, 2022 and 62,873,694 shares issued at December 31, 2021	65	61
Additional paid-in capital	992,964	964,401
Treasury stock, at cost; 1,994,198 shares at June 30, 2022 and December 31, 2021	(54,998)	(54,998)
Accumulated other comprehensive loss	(297)	(31)
Accumulated deficit	(1,229,432)	(1,106,377)
Total stockholders’ deficit	(291,698)	(196,944)
Total liabilities and stockholders’ deficit	$ 303,980	$ 381,590